Overview
- The $425 million financing is structured as a private investment in public equity and drew commitments from more than 60 institutional and crypto-native backers including Polychain Capital and GSR.
- Closing by August 1 will mark the formal conversion of the biotech firm’s treasury into ether, completing its shift from anti-inflammatory drug research to a crypto-focused reserve.
- Electric Capital is tapped to manage the ether holdings via an on-chain yield program that spans staking, lending and liquidity provisioning.
- A newly formed DeFi Council, featuring Etherealize and leaders from key Ethereum protocols, will guide treasury monetization and governance decisions.
- Following the announcement, 180 Life Sciences shares fell 7% to $2.69 as markets reacted to the firm's radical pivot toward decentralized finance.